BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 12, 2007
 |  BioCentury  |  Product Development

Nailing penetration

A key reason that topical treatments for onychomycosis have had suboptimal efficacy is their limited ability to penetrate the nail and nail bed to kill the fungus. Anacor Pharmaceuticals Inc. believes it has solved the problem with AN2690, which uses a simple water-soluble formulation to promote nail penetration. Schering-Plough Corp. apparently agrees, as it is paying $40 million up front for rights to the compound.

SGP (Kenilworth, N.J.) last week received an exclusive worldwide license to develop and commercialize AN2690, which is in Phase IIb testing. Anacor (Palo Alto, Calif.) also will receive a $10 million equity investment and is eligible for over $575 million in milestones, plus double-digit royalties. It also retains an option to co-promote AN2690...

Read the full 584 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >